| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF02093793 |
| P698 | PubMed publication ID | 8200260 |
| P2093 | author name string | T Suzuki | |
| A Matsumoto | |||
| K Kiyosawa | |||
| H Ogata | |||
| E Tanaka | |||
| P2860 | cites work | Avoiding false positives with PCR | Q29618606 |
| Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis | Q29619627 | ||
| Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources | Q29620774 | ||
| A second group of hepatitis C viruses | Q33240808 | ||
| The 5'-terminal sequence of the hepatitis C virus genome. | Q33943535 | ||
| The interferon system. A bird's eye view of its biochemistry | Q34248198 | ||
| Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment | Q37833358 | ||
| Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial | Q41839327 | ||
| Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial | Q42008293 | ||
| Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus | Q42981586 | ||
| The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients | Q42983268 | ||
| Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up | Q42983408 | ||
| Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus | Q42987918 | ||
| Clinical significance of antibodies to nonstructural and core proteins of hepatitis C virus in posttransfusion hepatitis patients during long‐term follow‐up | Q43038799 | ||
| Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease | Q43048269 | ||
| Interferon-induced chronic active hepatitis? | Q43466582 | ||
| Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa | Q68127333 | ||
| P433 | issue | 6 | |
| P921 | main subject | chronic hepatitis | Q62019625 |
| P304 | page(s) | 1273-1280 | |
| P577 | publication date | 1994-06-01 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. | |
| P478 | volume | 39 |
| Q42982450 | 2011 Japanese Society for Dialysis Therapy Guidelines for the Treatment of Hepatitis C Virus Infection in Dialysis Patients |
| Q42980838 | A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. |
| Q27485690 | Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology |
| Q42629438 | Analysis of T cell repertoire in the liver of patients with chronic hepatitis C. |
| Q42981859 | Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C. |
| Q50587343 | Characteristics of the hepatitis C virus and viral predictors of therapeutic response |
| Q33809456 | Clinical significance of hepatitis C virus genotypes. |
| Q42986175 | Clinical significance of hepatitis G virus infection in patients on long‐term haemodialysis |
| Q43029633 | Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver |
| Q27485773 | Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method |
| Q42990339 | Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations |
| Q45738503 | Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy |
| Q42980771 | Detection and typing of hepatitis C RNA in liver biopsies and its relation to histopathology |
| Q42982467 | Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C. |
| Q42980635 | Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases: a multi-institution analysis |
| Q43001190 | Eradication of hepatitis C virus 1b by interferon in a health care worker with acute hepatitis following needlestick transmission from a patient with chronic hepatitis C unresponsive to interferon |
| Q42999502 | Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. |
| Q42988988 | Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion‐associated non‐A, non‐B hepatitis |
| Q42994719 | Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region |
| Q27486520 | Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China |
| Q33961960 | Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. |
| Q43035147 | Genotypes and virus load in patients with hepatitis C infection |
| Q58803503 | HCV viraemia is more important than genotype as a predictor of response to interferon in sicily (Southern Italy) |
| Q35938587 | Hepatitis C virus genotypes in Korea and their relationship to clinical outcome in type C chronic liver diseases |
| Q41958799 | Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome |
| Q39455553 | Hepatitis C virus quantitation: optimization of strategies for detecting low-level viremia. |
| Q36642065 | Hepatitis C: progress and problems |
| Q71706611 | Hepatocyte regeneration in chronic hepatitis C and interferon treatment: analysis of immunohistological identification of proliferating cell nuclear antigen (PCNA) |
| Q43658088 | Human leucocyte interferon-alpha in the treatment of chronic hepatitis C. |
| Q27491312 | Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C |
| Q47123261 | In-Vitro Transcription analysis of NS5A from HCV-3a circulating in Pakistani patients with chronic hepatitis C and their differential response to antiviral therapy |
| Q42981181 | Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection |
| Q31083635 | Interferon for interferon naive patients with chronic hepatitis C. |
| Q40961282 | Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis |
| Q42979393 | Lymphocyte proliferative responses to recombinant hepatitis C virus antigens in patients with chronic hepatitis C. |
| Q58622847 | Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update |
| Q27472593 | Past and Present Hepatitis G Virus Infections in Areas Where Hepatitis C is Highly Endemic and Those Where It Is Not Endemic |
| Q33808119 | Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network |
| Q42996606 | Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy |
| Q45755300 | Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon |
| Q42981053 | Predictors of response to interferon therapy |
| Q42982312 | Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors |
| Q40888842 | Quantitative measurement of HCV RNA in the serum: A comparison of three assays based on different principles |
| Q42982877 | Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon |
| Q43031106 | Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study |
| Q42998252 | Relationship between histological prognosis of chronic hepatitis C and amount of hepatitis C virus core protein in serum |
| Q42979741 | Relationship between pretreatment viremia level and response to interferon-alpha therapy in chronic hepatitis C differs in viral type 1 and 2 infections |
| Q42989240 | Review article: interferon and hepatitis C—factors predicting therapeutic outcome |
| Q45733166 | SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. |
| Q43037280 | Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients |
| Q43049090 | Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon |
| Q73483382 | The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis |
| Q35817765 | The use of whey protein concentrate in management of chronic hepatitis C virus - a pilot study |
| Q43982980 | Therapy of hepatitis C |
| Q43038107 | Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon α2a therapy |
| Q43031174 | Variations within hepatitis C virus E2 protein and response to interferon treatment |
Search more.